SCP & CO Healthcare Acquisition Company Warrant
SHACW
SHACW was delisted on the 8th of December, 2022.
0 hedge funds and large institutions have $0 invested in SCP & CO Healthcare Acquisition Company Warrant in 2022 Q4 according to their latest regulatory filings, with 0 funds opening new positions, 0 increasing their positions, 0 reducing their positions, and 53 closing their positions.
100% less funds holding
Funds holding: 53 → 0 (-53)
100% less capital invested
Capital invested by funds: $8.22M → $0 (-$8.22M)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 53
Top Buyers
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
MP
Mangrove Partners
Greenwich,
Connecticut
|
-$4.93M |
| 2 |
RCM
Radcliffe Capital Management
Bala Cynwyd,
Pennsylvania
|
-$2.34M |
| 3 |
LP
LMR Partners
London,
United Kingdom
|
-$493K |
| 4 |
SCM
Segantii Capital Management
Hong Kong
|
-$123K |
| 5 |
Nomura Holdings
Tokyo,
Japan
|
-$45K |
SHACW Hedge Fund Activity: Q4 2022 in Review
0 of the 6,221 institutional investors tracked by Wall St. Rank reported a position in SCP & CO Healthcare Acquisition Company Warrant (SHACW) for Q4 2022, worth a combined $0 — down 100% from $8.22M a quarter earlier.
Sellers outnumbered buyers: 53 funds closed out of SHACW and 0 opened new positions — a net loss of 53 holders — while 0 trimmed existing stakes and 0 added.
The largest seller was Mangrove Partners, exiting entirely with an estimated $4.93M sold.
- 0 institutional investors held SCP & CO Healthcare Acquisition Company Warrant (SHACW) as of Q4 2022, down from 53 in Q3 2022.
- Funds reported $0 of SCP & CO Healthcare Acquisition Company Warrant stock for Q4 2022, down 100% quarter-over-quarter.
- 0 funds opened new SCP & CO Healthcare Acquisition Company Warrant positions in Q4 2022 and 53 closed out, a net change of -53 holders.
- The largest SCP & CO Healthcare Acquisition Company Warrant seller in Q4 2022 was Mangrove Partners, an estimated $4.93M sold.
Based on aggregated 13F filings for Q4 2022.